Physician profile
Peter Wenn
NPI 1073019337
$5,267.57
in general payments reported to CMS, 2019-2025
16 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $233 · 2023: $1,353 · 2024: $1,510 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $2,190 · Food and Beverage: $1,847 · Travel and Lodging: $998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $2,189.72 |
| Food and Beverage | $1,846.63 |
| Travel and Lodging | $997.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,351.45 | 2023-2025 | General - Vascular Access, Avvigo Guidance System, General - Therapies |
| Shockwave Medical, INC | $500.99 | 2025 | |
| Abbott Laboratories | $370.74 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Diamondback Coronary, Aveir |
| Medtronic, INC. | $209.40 | 2023-2024 | Symplicity G3, Corevalve Evolut R |
| Pfizer INC. | $143.81 | 2022-2023 | |
| Stryker Corporation | $134.71 | 2025 | Clottriever Bold Catheter |
| Amgen INC. | $134.40 | 2022-2024 | Repatha |
| Heartflow, INC. | $106.11 | 2025 | |
| Astellas Pharma US INC | $87.99 | 2022 | |
| Bard Peripheral Vascular, INC. | $54.25 | 2025 | Crosser Iq |
| Abiomed | $43.32 | 2025 | |
| Kestra Medical Technology Services, INC. | $36.06 | 2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $28.69 | 2024 | Camzyos |
| Lantheus Medical Imaging, INC. | $25.13 | 2024 | |
| Scpharmaceuticals INC. | $20.50 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $20.02 | 2023 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wenn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.